Search Results 831-840 of 37953 for Two-phase

1. Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck - Mayo Clinic

   Study phase. 2/3. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase ( ...

2. Polycythemia Vera Clinical Trials - Mayo Clinic Research

   Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 or Phase 3 study and meet the inclusion/exclusion criteria for this ...

3. Phase 3 Study Of Daraxonrasib (RMC-6236) In Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - Mayo Clinic

   Study phase. 3. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase ...

4. Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) with Avelumab in Muscle Invasive Bladder Cancer - Mayo Clinic

   Study phase. 2. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase ...

5. A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis - Mayo Clinic

   This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that ...

6. A Study To Evaluate The Safety And Efficacy Of A2B395, An Allogeneic Logic-gated CAR T, In Participants With Solid Tumors That Express EGFR And Have Lost HLA-A*02 Expression - Mayo Clinic

   Study phase. 1/2. During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase ( ...

7. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

   During an initial Dose Evaluation phase (first 2 cycles) to determine Dose Limiting Toxicities (DLTs), dose combinations of pembrolizumab 200 mg followed by ...

8. Study of BMF-219, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

   The purpose of this study is to determine the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D) of BMF-219 monotherapy (Cohorts 1, 2, 3, and 4).

9. Tolerability, safety and deep response found in cevostamab phase 1 trial - Mayo Clinic

   "At the ASH meeting, everyone agreed that the bispecific antibody presentations in multiple myeloma — of which this was one of two — were deemed the most ...

10. Menopause - Symptoms and causes - Mayo Clinic

    Perimenopause can last 2 to 8 years. The average ... Accessed April 2, 2024. Casper RF. Clinical ... Menopause stages, symptoms, & signs. North ...